LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net selling: insiders sold $84.4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $84.4M and bought $0 of NTRA stock on the open market in the 90 days to Oct 16, 2026, according to SEC Form 4 filings. $84.4M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Rabinowitz, Matthew (Executive Chairman), who sold $52.5M. The latest filing was on Oct 3, 2026.
None. No member of Congress disclosed a NTRA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 16, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (3)
D.E. Shaw
$249.0M
added
Viking Global
$106.1M
bought
Squarepoint
$91.3M
bought
No tracked top-trader positions in NTRA right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 6, 2026
Financial period
Q2 2026
Adjusted EPS
-$0.53 expected
Revenue
$661.3M expected
2026 guidance
$2.85B to $2.91B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | -$0.47 / -$0.53Yahoo Finance | +11.99% beat | $752.8M / $661.3M | +13.84% beat |
| Mar 31, 2026 | May 7, 2026 | -$0.60 / -$0.55Yahoo Finance | -8.52% miss | $696.6M / Unavailable | Unavailable |
| Dec 31, 2025 | Feb 26, 2026 | $0.36 / -$0.53Yahoo Finance | +$0.89 beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | -$0.64 / -$0.35Yahoo Finance | -80.73% miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | -$0.74 / -$0.60Alpha Vantage | -23.33% miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 8, 2025 | -$0.50 / -$0.66Alpha Vantage | +24.24% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 27, 2025 | -$0.41 / -$0.35Alpha Vantage | -18.29% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 12, 2024 | -$0.26 / -$0.59Alpha Vantage | +55.93% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 15, 2026
EPS expected
-$0.61 to $0.13
Revenue expected
19 analysts
Last 30 days
Analysts raising estimates
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $592.2M | $665.5M | $696.6M | $752.8M |
| Cost of what it sold | $207.8M | $218.7M | $245.2M | $267.6M |
| Gross profit | $384.4M | $446.8M | $451.4M | $485.2M |
| What it spent | ||||
| Research and development | $173.4M | $175.2M | $210.7M | $228.1M |
| Sales and admin | $308.5M | $291.3M | $327.9M | $327.2M |
| Other operating costs | — | — | $6.3M | $5.7M |
| Total operating expenses | $482.0M | $469.6M | $545.0M | $561.0M |
| What was left | ||||
| Operating profit | -$97.6M | -$22.8M | -$93.5M | -$75.8M |
| Interest on debt | $1.0M | $7.1M | $892.0K | $890.0K |
| Profit before tax | -$87.3M | -$13.3M | -$84.8M | -$67.2M |
| Tax | $207.0K | -$60.6M | $283.0K | -$261.0K |
| Net profit | -$87.5M | $47.3M | -$85.1M | -$67.0M |
| EBITDA | -$76.0M | $7.9M | -$65.5M | -$45.2M |
This stock is trending upward.
Trend
Constructive
65 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
FDA Grants Breakthrough Device Designation to Natera's Multi-Cancer Early Detection Blood Test
Leans bullishOct 14Natera's Multi-Cancer Blood Test Gets FDA Breakthrough Status, a Faster Review Path That Is Not an Approval
NeutralOct 14Natera and TransCode announce Phase 2a collaboration: Natera stock pre-market at EUR 354.00
Leans bullishOct 14NTRA Maintained by TD Cowen -- Price Target Raised to $480
Leans bullishOct 13Natera
NeutralOct 13No approved treatment exists for colorectal cancer patients with cancer signals but clear scans. A trial will test one.
NeutralOct 13Natera to Provide MRD Testing for TransCode Therapeutics CRC Trial Recruitment
Leans bullishOct 13Form 4 Natera Inc For: 12 October By Investing.com
NeutralOct 13